Press Releases

Summary Toggle Arbutus to Participate in Upcoming Investor Conferences

Feb 09, 2017

Arbutus to Participate in Upcoming Investor Conferences 14.7 KB

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in upcoming investor conferences....

Read more
Summary Toggle Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology

Feb 08, 2017

Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology 17.1 KB

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced that the Supreme Court of...

Read more
Summary Toggle Arbutus Provides Additional Data from the ARB-1467 Phase II Clinical Trial in HBV Patients

Dec 12, 2016

Arbutus Provides Additional Data from the ARB-1467 Phase II Clinical Trial in HBV Patients 25.4 KB

Complete Cohort 1 and 2 ARB-1467 Multi-Dose Data Demonstrate Dose-Responsive HBsAg Reductions Greater Than 1.0 log 10 Reduction in Serum HBsAg Observed in 3/5 Patients After Receiving Three Monthly Doses of ARB-1467 at 0.4 mg/kg Company to Host Conference Call to Review Phase II Data and Recent...

Read more
Summary Toggle Arbutus Presents HBV Drug Combination Studies at AASLD

Nov 14, 2016

Arbutus Presents HBV Drug Combination Studies at AASLD 19.3 KB

Combinations of Arbutus RNAi and Capsid Assets and Approved Drugs Show Complementary Action Capsid Inhibitor AB-423 Has Dual Mode of Action; Inhibits HBV DNA and cccDNA Synthesis Second Generation RNAi Agent ARB-1740 Improves Upon Potency of Lead RNAi Program VANCOUVER, B.C....

Read more
Summary Toggle Arbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results

Nov 03, 2016

Arbutus Provides Corporate Update and Announces Third Quarter 2016 Financial Results 40.4 KB

Additional ARB-1467 Multi-Dose Data in 4Q16 Cash Runway into Late 2018 VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced its third quarter...

Read more
Summary Toggle Arbutus Recognizes Liver Cancer Awareness Month with Grant to Support the Hepatitis B Foundation's Patient Storytelling Campaign

Oct 03, 2016

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a partnership with the Hepatitis B Foundation to support the Patient...

Read more
Summary Toggle Arbutus to Present HBV Data at the 2016 AASLD Liver Meeting

Oct 01, 2016

Arbutus to Present HBV Data at the 2016 AASLD Liver Meeting 21.5 KB

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Oct. 01, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today announced presentation of data at the 2016 American Association for the Study of Liver...

Read more
Summary Toggle Arbutus Reports Interim Multi-Dose Results from Phase II Clinical Trial of ARB-1467 in Patients with Chronic HBV Infection

Sep 29, 2016

Arbutus Reports Interim Multi-Dose Results from Phase II Clinical Trial of ARB-1467 in Patients with Chronic HBV Infection 23.6 KB

Single Dose Data Demonstrate Significant Reduction in Serum HBsAg Additive Reductions in Serum HBsAg Observed with Repeat Dosing over 3 Months 5 of 6 Patients in Cohort 1 Had Serum HBsAg Reductions of Greater Than 0.5 log 10 After 3 Doses Additional Multi-Dose ARB-1467 Data Expected in 4Q16 Company...

Read more
Summary Toggle Arbutus' Chief Scientific Officer, Dr. Michael J. Sofia, Awarded the 2016 Lasker~DeBakey Clinical Medical Research Award

Sep 13, 2016

Arbutus' Chief Scientific Officer, Dr. Michael J. Sofia, Awarded the 2016 Lasker~DeBakey Clinical Medical Research Award 13.4 KB

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael J. Sofia, Arbutus' Chief Scientific Officer, has been awarded...

Read more
Summary Toggle Arbutus to Present at the 2016 Wedbush PacGrow Healthcare Conference

Aug 10, 2016

Arbutus to Present at the 2016 Wedbush PacGrow Healthcare Conference 11 KB

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be presenting at the Wedbush PacGrow Healthcare Conference...

Read more